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Further developments in instrumentation to acquire data
from a complete TMA are necessary. Conventional microscopy
methods must be significantly adapted to acquire, in an unsuper-
vised manner, images from the complete array, as is required to
preserve spatial information and relationships. Large numbers
of images are eventually ‘stitched’ together to provide a complete
image. Continuous automatic focusing methods are essential to
preserve sub-cellular resolutions. Although the work is currently
slow, results are very precise and accurate.
THE FUTURE: Currently, we are moving away from normal
microscopy platforms for this type of work. Under development
is a prototype imaging station dedicated to high-throughput
work. This arrangement eliminates traditional approaches and
is equally suited to acquiring data from other ‘large-area’ sam-
ples. An obvious example is the use of high-density multiwell
plates for assays involving drug action. One of the current rate-
limiting steps is the use of scanned optical beams and single-
point detection.10–13 Highly parallel time-resolved detectors are
however under development and the future of this technique will
be dependant on complementary highly parallel signal process-
ing instrumentation. Furthermore, data handling and analysis
requires multiprocessor computer architectures and a high level
of automation.
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Matrix-assisted laser desorption/ionisation (MALDI) is a ‘soft’ ion-
isation technique that most often uses a time-of-flight (TOF) mass
spectrometer. The advantage of MALDI-TOF TOF mass spectrom-
etry (MS) over alternative approaches are ease of use, simple sam-
ple preparation and high throughput, rendering it an ideal tool for
large scale clinical application.1 Using MALDI-TOF MS for clinical
specimens can yield important information about disease state,
drug response and/or efficacy, and drug toxicities. It can also be
used to analyse biomolecules that could serve as classifiers to
determine which patients will most likely respond to certain
molecularly targeted therapies. The use of MALDI-TOF MS as a
clinical tool has been overshadowed by some notable failures.
Focusing on reproducibility and validation, we have shown that
MALDI-TOF MS can be successfully applied to protein profiling
in a clinical setting.
MASS SPECTROSCOPY AS A DIAGNOSTICS TOOL: Achieving
sufficient reproducibility in mass spectrometry for use in a clini-
cal setting is hardly a trivial issue. Mass spectra can be highly var-
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iable for a multitude of reasons: First, variations in instrument
settings and performance, and operator performance. Second,
variations in sample preparation (freeze/thaw cycles), open time,
and pre-treatment (fractionation) can lead to non-reproducible
data. Third, biological and population variations (age, gender,
race, digestive state, etc.) need to be considered, identified and
quantitatively measured.
The success of MALDI-TOF MS profiling hinges on sensitive
and robust data analysis algorithms to render mass spectra com-
parable across different laboratories and instruments.
If the goal is to use mass spectroscopy in clinical practice
instead of a research only tool, the methods used must be trans-
parent to the physician and to the patient. A ‘black box’ approach
will not be acceptable. Work flow is another consideration for the
clinical setting; the system should be uncomplicated and robust,
bearing in mind that this is a high-throughput technique.
VERISTRAT DEVELOPMENT: As an example of using proteomics
technique Dr. Roder presented the development of VeriStrat, a
mass spec based test, to select beneficiaries of EGFR-TKIs from
pre-treatment serum or plasma samples. Competing tests are
based on genomic analysis. These include EGFR copy number,
determined by fluorescent in situ hybridisation (FISH), and muta-
tion analysis, both of which requires large tissue samples. FISH
appears to be more predictive for survival thanmutation analysis;
however, it is time intensive, costly and technically intensive.
Clearly, a need exists for alternative means of identifying the
patients who would most likely respond to EGFR-TKIs.
VeriStrat is a serum/plasma diagnostics system for stratifying
non-small-cell lung cancer (NSCLC) patients based on response to
epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) such as erlotinib (Tarceva) or gefitinib (Iressa).
Patient stratification is important because only a subset of
patients derive clinical benefit from EGFR-TKIs, treatment cost
is high, and alternatives exist. Additionally, increasing evidence
indicates that treatment with EGFR-TKIs could be potentially
harmful for non-responders. Stratification is also important for
possibly extending use of these anticancer agents as first-line
treatments. Approval would depend on a true end-point, not
tumour response, because it does not correlate with overall
survival.
To test the MALDI-TOF/VeriStrat system, serum or plasma
samples from six institutions were used to assemble a training
sample set, a test set and two control sets. Two laboratories tested
the samples independently. Using the training set, a classifier of
disease progression was developed (stable disease, progressive
disease, partial response, early progressive disease). It was found
that if the classifier was trained for extreme cases (stable disease
classified as ‘good’ and early progressive disease as ‘bad’) it had a
strong correlation with survival. Subsequent testing showed that
patient classification was very reproducible in two laboratories.
Spectra were generated at two institutions and VeriStrat was
applied independently. The classification results showed very
good agreement despite use of different instruments and lack of
standardised operating procedures.2
Other patient subgroups have also been studied and the ability
of VeriStrat to select patients with good prognosis on EGFR-TKIs
was also possible for the subgroups of smokers and squamous
cell patients. Concordance was very good, both for tests per-
formed in different institutions on the same samples, and when
plasma and serum samples were compared. Multivariate analysis
of data based on VeriStrat testing of plasma samples from
patients treated with erlotinib (Tarceva) as a first-line drug
showed that weight loss, performance status and the number of
involved sites were independently significant, but VeriStrat
remained a significant predictor even under the inclusion of these
co-factors.
CONCLUSION: In summary, a simple mass spectroscopy-based
pre-treatment patient selection system was established that is
highly reproducible and capable of classifying patients by sur-
vival. It is specific for EGFR-TKI treatment and is capable of distin-
guishing patient subgroups with respect to covariates.
Prospective trials are being planned based upon use of VeriStrat.
In further studies we plan to combine proteomic and genomic
markers, develop markers earlier and find reliable prognostic
tools for other indications. The chance for success using VeriStrat
is based on its low cost and high throughput. Commercialisation
efforts are under way, including discussions with commercial lab-
oratories and regulators. It would probably be advisable to use a
centralised laboratory model at this point for upcoming trials.
Other types of samples, based upon where one would expect to
find markers for a specific disease may also be used. In general,
it is important to consider how abundant the material is.
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